Table 3. Platelet reactivity during antiplatelet therapy.

Variables	CLPD group (n=20)	CILO group (n=20)	PUFA group (n=20)	p
ADP, 10 µM (%)
Aspirin monotherapy	64.7±16.8	67.6±11.6	70.2±9.2	0.403
Combination therapy	48.4±19.9	58.8±16.2	67.8±9.2	0.001
LS mean difference	16.1	8.8	2.4
95% CI of difference	6.0 to 26.4	1.3 to 16.4	−3.2 to 8.0
p value	0.004	0.024	0.379
TRAP, 25 µM (%)
Aspirin monotherapy	59.7±16.6	62.8±18.8	65.4±14.1	0.561
Combination therapy	48.0±26.1	50.0±15.8	60.7±18.6	0.119
LS mean difference	11.8	12.8	4.6
95% CI of difference	−1.3 to 24.8	−1.3 to 24.8	−4.9 to 14.1
p value	0.075	0.012	0.319
Collagen, 6 µg/dL (%)
Aspirin monotherapy	60.7±15.7	62.2±18.5	68.2±11.4	0.272
Combination therapy	54.8±21.0	50.9±18.5	59.8±14.9	0.312
LS mean difference	5.9	11.3	8.4
95% CI of difference	−4.1 to 15.8	3.9 to 18.7	0.8 to 16.1
p value	0.233	0.005	0.033
Arachidonic acid, 0.5 mg/dL (%)
Aspirin monotherapy	20.7±14.6	23.5±17.2	28.1±21.0	0.423
Combination therapy	20.9±15.5	12.0±8.6	20.5±13.9	0.059
LS mean difference	−0.2	11.4	7.6
95% CI of difference	−4.3 to 3.9	3.4 to 19.5	−0.5 to 15.7
p value	0.906	0.008	0.066

Values are presented as mean±standard deviation or number (%). CLPD: clopidogrel, CILO: cilostazol, PUFA: omega-3 polyunsaturated fatty acid, ADP: adenosine diphosphate, LS: least mean square, CI: confidence interval, TRAP: thrombin receptor agonist peptide